Leksum LLC, an early-stage life sciences company based in Boston, Massachusetts, has signed an agreement with the Department of Anesthesia, Intensive Care Medicine and Pain Medicine at the Medical University of Vienna. The agreement, which also includes Phoenestra GmbH as a co-signatory, covers preparatory work leading up to Phase I/II first-in-human clinical trials for LK-ICU, a biologic therapy designed to address acquired muscle myopathies. The significance of this announcement lies in its potential to address a widespread and serious complication of critical care: diaphragm muscle weakness and wasting that occurs during mechanical ventilation, a condition known as ICU-acquired weakness. This condition often leads to extended weaning from ventilators and significantly impacts the quality of life of hundreds of thousands of patients annually in the U.S. and Europe.
Preclinical studies of LK-ICU, which consists of extracellular vesicles derived from bone marrow mesenchymal stromal cells, have shown an almost complete preservation of both diaphragm muscle fiber size and function that is normally lost with mechanical ventilation. These findings suggest that LK-ICU could become a first-in-class therapy to prevent or reduce diaphragm atrophy in critically ill patients, potentially shortening ventilator dependence and improving recovery. The agreement with the Medical University of Vienna represents a critical step in translating these preclinical results into clinical evaluation. For a more detailed view of the announcement, including downloadable images and bios, click here.
Leksum plans to commence efforts under the agreement upon closing its Series A financing round. The planning phase is expected to last several months, after which the company intends to initiate Phase I/II trials. Importantly, Leksum aims to use European clinical data to support its U.S. regulatory path, a strategy that could accelerate the therapy's development and approval in the United States. This cross-continental approach may also facilitate broader acceptance and adoption of LK-ICU if it proves successful. The company's pipeline extends beyond LK-ICU to include other skeletal muscle conditions such as sarcopenia, cancer cachexia, and muscle loss due to the use of weight-loss drugs like GLP-1s. This broader focus underscores Leksum's commitment to addressing muscle-wasting disorders across multiple patient populations.
The collaboration with the Medical University of Vienna, a leading European academic medical center, lends scientific credibility and clinical expertise to the LK-ICU program. It also highlights the growing interest in extracellular vesicle-based therapies, which harness the regenerative potential of mesenchymal stromal cells without the complexities of whole-cell transplantation. For patients suffering from ICU-acquired weakness, the implications are profound: a therapy that preserves diaphragm function could reduce the duration of mechanical ventilation, lower the risk of complications, and improve long-term outcomes. As Leksum advances toward clinical trials, the agreement marks a pivotal moment in the development of a novel treatment for a condition that currently lacks effective pharmacological options. More information about Leksum and its pipeline is available through its official announcements.
